


15th Meeting of the IBCN
October 21st – 23rd, 2017

at the
Fundação Champalimaud
Lisbon, Portugal



Program 15th Meeting of the IBCN

October 21st – 23rd, 2017 at the Fundação Champalimaud in Lisbon, Portugal

SATURDAY, OCTOBER 21st, 2017

19:00 Welcome Dinner (*Marriott Hotel*)



For those who stay at the Hotel and/or are already in the city:
we will have the traditional “get-together” the evening prior to the meeting.
This is an informal buffet dinner at the hotel in a separate area of the restaurant starting at 7 pm.


SUNDAY, OCTOBER 22nd, 2017

7.00 Bus pickup at Marriott Hotel

Introduction	Topic	Speaker
07:30 – 07:45	Registration	
07:45 – 07:50	Welcome to IBCN Meeting	Goebell/Kamat
07:50 – 08:00	Welcome to Lisbon	Cordon-Cardo

Abstract Session I

	Biomarkers	Schmitz-Dräger
08:00 – 08:07	The role of germline genetic variants in the prognosis of non-muscle invasive bladder cancer: a meta-GWAS	Kiemenev
08:07 – 08:14	Prospective validation of a diagnostic urine test for bladder cancer: The HEMAturia study	van Kessel
08:14 – 08:21	Biomarker classifiers for detection of bladder cancer in patients with haematuria are confounded by smoking and increased age	Williamson
08:21 – 08:30	Discussion	
08:30 – 08:37	Choline Phosphate Cytidylyltransferase- α as a Novel Predictor of Response to Neoadjuvant Chemotherapy	Segersten
08:37 – 08:44	Bcl-2 as a Predictive Marker of Neoadjuvant Chemotherapy Response	Turker
08:44 – 08:51	Predictive biomarkers in urinary bladder cancer – validation studies in a biobank based on controlled prospective trials	Malmström
08:51 – 09:00	Discussion	
09:00 – 09:07	Inherent and acquired mechanisms of cisplatin resistance	Skowron
09:07 – 09:14	Survivin and ERCC-1 as prognostic factors in patients with MIBC	Kiani
09:14 – 09:21	Association Between Epithelial Tumor Marker Trends and Oncological Outcomes	Daneshmand
09:21 – 09:30	Discussion	



Program 15th Meeting of the IBCN

October 21st – 23rd, 2017 at the Fundação Champalimaud in Lisbon, Portugal

Abstract Session II

	Bladder Cancer Models	Grossman
09:30 – 09:45	Urothelial organoids: a novel culture method for bladder cancer	Mullenders
09:45 – 09:52	A Mouse Model for Carcinogen-induced Bladder Cancer Recapitulates the Epigenetic Signature and the Machinery of the Human Disease	Meeks
09:52 – 09:59	CD49f labels an organoid-forming mouse urothelial cell population with stem cell features	Pereira Santos
09:59 – 10:06	Assessment of acute bowel toxicity from chemoradiation for bladder cancer using an <i>in vivo</i> gastrointestinal crypt assay and <i>in vitro</i> organoid system	Kiltie
10:06 – 10:13	A <i>normal</i> perspective on bladder cancer	Southgate
10:13 – 10:30	Discussion	

Break 10:30 – 10:45

Pipeline Talks

Pipeline	Topic	Kamat
10:45 – 11:15	The I-O development in Bladder Cancer	Dambacher
11:15 – 11:45	Clinical results of methylation-based multi-marker urine assay for monitoring	Grossman
11:45 – 12:15	Next Generation Epigenetic Biomarkers for Bladder Cancer.	Van Criekinge
12:15 – 12:45	Is there a role for Blue Light Flexible Cystoscopy in the surveillance of Non-Muscle Invasive Bladder Cancer? Results of a prospective multicenter trial.	Kamal Pohar
12:45 – 13:15	TARIS Technology Update in Urothelial Carcinoma	Cutie


13:15 attendees take lunch to Break-out sessions

IBCN meets Industry – Break-out Sessions (13:30 – 14:30)

Company		Moderators
BMS	Checkpoint blockade - beyond the promise	Dambacher & Goebell
Nucleix	Road to clinical adoption and pragmatic barriers for novel urine markers	Grossmann & Shuali
MDx Health	Epigenetic biomarkers in bladder cancer	Witjes & Van Criekinge
Photocure	Flexible blue light cystoscopy	Kamal & Bellette
Taris	Synergy between local cytotoxic and systemic checkpoint blockade	Kamat & Cutie

Keynote

	Topic	Black
14:30 – 14:50	The Microbiota: A New Variable Impacting Cancer Immunotherapy Outcomes	Tom Gajewski
14:50 – 15:00	Discussion	



Program 15th Meeting of the IBCN

October 21st – 23rd, 2017 at the Fundação Champalimaud in Lisbon, Portugal

Abstract Session III		
	Bladder Tumor Immunology	Black
15:00 – 15:07	Genomic analysis of bladder cancer immunophenotypes	Sweis
15:07 – 15:14	Comprehensive immune profiling of patients with urothelial carcinoma of the bladder identifies a novel immune target	Sfakianos
15:14 – 15:21	Comparison of cellular composition and expression of PD-L1/PD1 in urine and blood cells from patients with muscle-invasive bladder cancer (MIBC) with or without neoadjuvant chemotherapy	Rodriguez Faba
15:21 – 15:30	Discussion	
15:30 – 15:37	Improving immune-gene therapy for bladder cancer	Dinney
15:37 – 15:44	PD-L1 and PD-1 expression patterns in Patients with NMIBC undergoing Intravesical BCG	Kates
15:44 – 15:50	Discussion	
15:50 – 16:05	Response prediction to immune checkpoint therapy in bladder cancer- harmonization of PD-L1 immunohistochemistry and beyond	Hartmann
16:05 – 16:15	Discussion	
16:15 – 16:22	Correlation between Confocal laser endomicroscopy (Cellvizio®) and histological grading of upper tract urothelial carcinoma: a step forward for a better selection of patients suitable for conservative management	Palou
16:22 – 16:25	Discussion	

Health break 16:25 – 16:40

	Clinical trials – room for improvement	Goebell
16:40 – 16:50	Trial design for BCG unresponsive NMIBC	Kamat
16:50 – 17:00	The rise and fall of the neoadjuvant paradigm for drug development	Dinney
17:00 – 17:10	Focus on biomarker-driven clinical trial design in bladder cancer	Flaig
17:10 – 17:20	Building on past failures - new approaches to clinical trials for MIBC	Stadler
17:20 – 18:00	Panel Discussion Kamat/Dinney/Flaig/Stadler/Apolo	


Adjourn

18:00 – 18:10	Summary	Kamat/Goebell
---------------	---------	---------------

18:15 Bus return to Marriott Hotel

IBCN dinner

20:00	Bus pick-up Marriott Hotel for IBCN Dinner Restaurante DOC COD
22:30	Bus return to Marriott Hotel



Program 15th Meeting of the IBCN

October 21st – 23rd, 2017 at the Fundação Champalimaud in Lisbon, Portugal

MONDAY, OCTOBER 23rd, 2017

7.00 Bus pickup at Marriott Hotel


07:30 – 08:30	IBCN – General Assembly	Members only
---------------	-------------------------	--------------

Keynote		
	Topic	Goebell
08:30 – 08:50	Molecular Pathology in Bladder Cancer	Cordon-Cardo
08:50 – 09:00	Discussion	

Abstract Session IV		
	Molecular Subtyping	McConkey
09:00 – 09:07	Molecular subtypes in progression from early to muscle-invasive bladder cancer	Sjödahl
09:07 – 09:14	Validation of the Lund taxonomy classification of advanced urothelial carcinomas: Urothelial-like tumors show a large phenotypic and genomic heterogeneity	Höglund
09:14 – 09:21	Specific risk patterns for bladder cancer taxonomy-based subphenotypes	Dominguez
09:21 – 09:36	Non-Coding RNA modulate molecular subtype biology in muscle invasive bladder cancer (MIBC) and are independently associated with survival	Lerner
09:36 – 09:49	Discussion	
09:49 – 09:56	Predictive impact of intrinsic bladder cancer subtypes on survival after radical cystectomy	Sundi
09:56 – 10:03	Plasticity in muscle-invasive bladder cancer before and after cisplatin-based neoadjuvant chemotherapy	Seiler
10:03 – 10:10	Proteomics phenotyping of bladder cancer	Vlahou
10:10 – 10:17	Cytochrome P450 activity in muscle-invasive bladder cancer: a novel sub-group	Baker
10:17 – 10:30	Discussion	

Health break 10:30 – 10:45		
-----------------------------------	--	--

Abstract Session V		
	Bladder Cancer Progression	Nawroth
10:45 – 10:52	Tumor-associated exosomes play a crucial role in the cell-cell communication in bladder cancer	Junker
10:52 – 10:59	Molecular Characterization of Field Effects and Their Progression to Clinically Evident Bladder Cancer	Czerniak
10:59 – 11:06	Progression to Sarcomatoid Bladder Cancer is Associated with Dysregulation of Chromatin Remodeling and Cell Cycle Circuits	Guo
11:06 – 11:13	Shedding light into the role of STAG2 in bladder cancer	Lapi
11:13 – 11:20	Discussion	



Program 15th Meeting of the IBCN

October 21st – 23rd, 2017 at the Fundação Champalimaud in Lisbon, Portugal


Keynote		
	Topic	Nawroth
11:20 – 11:40	Circulating tumor Cells	Cordon-Cardo
11:40 – 11:50	Discussion	

Visit to the Fundação Champalimaud 11:50– 12:30



Lunchbreak 12:30 – 13:30

Abstract Session VI		
	Novel targets	Dinney
13:30 – 13:37	Combined pharmacological inhibition of BRD proteins and class-I HDACs synergistically induces apoptosis in urothelial carcinoma cells	Hoffmann
13:37 – 13:44	A Mouse Model of Bladder-Specific Over-Expression of NOTCH2 Confirms the Oncogenic Role of NOTCH2 in Bladder Cancer	Contreras-Sanz
13:44 – 13:51	Cdk4 as therapeutic target in bladder cancer	Paramio
13:51 – 14:00	Discussion	
14:00 – 14:07	Comprehensive analysis of Sirtuin family expression in bladder urothelial carcinoma	Jerónimo
14:07 – 14:14	The retinoid system in non-muscle-invasive bladder tumors	Isfoss
14:14 – 14:21	Dysregulation of Estrogen Receptor B Pathway as a Mechanism of Bacillus Calmette-Guérin Resistance in Bladder Cancer	Smith
14:21 – 14:30	Discussion	



Program 15th Meeting of the IBCN

October 21st – 23rd, 2017 at the Fundação Champalimaud in Lisbon, Portugal

Abstract Session VII		
Clinical	Topic	Taylor
14:30 – 14:37	Long-Term Survival after Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Peritoneal Carcinomatosis of Urachal Cancer	Mertens
14:37 – 14:44	Survival Differences Among Bladder Cancer Patients According to Gender: Critical Evaluation of Radical Cystectomy Use and Delay to Treatment	Williams
14:44 – 14:51	Cost-Effectiveness of Robot-Assisted Radical Cystectomy Using a Propensity Matched Cohort	Navai
14:51 – 15:00	Discussion	
15:00 – 15:07	Safety and efficacy of enzalutamide and gemcitabine and cisplatin in metastatic bladder cancer	Gupta
15:07 – 15:14	Hyperthermic intravesical chemotherapy for BCG unresponsive or BCG ineligible non-muscle invasive bladder cancer	de Jong
15:14 – 15:20	Discussion	

Wrap-Up & Closing Remarks	
15:20	Kamat and Goebell

15:45 Bus return to Marriott Hotel